Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial for LNTH-2401
Bitget2026/09/28 12:04- Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational study of LNTH-2401 PET imaging in prostate cancer.
- No clinical results were presented; the trial is designed to generate data for a future diagnostic performance readout.
- The study aims to show LNTH-2401 can help detect and characterize prostate cancer using a GRPR-targeted approach complementary to PSMA imaging.
- Phase 3 is expected to enroll about 400 participants, positioning the program as a potential pipeline expansion in prostate cancer imaging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The new Roadster is about to debut: Is "Tesla can fly" just hype or reality?
BUZZ - Super Micro appoints Mark Long as Chief Financial Officer; shares fall
The US stock market opened mixed, with the Nasdaq down 331 points.
"Super bull" Yardeni lowers S&P year-end target: Earnings are not the problem, valuation is
Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.
Crypto prices
More
